Encouragingly, Liu et al. have demonstrated that targeting METTL1-mediated tRNA modification reduces polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and improves anti-PD-1 efficacy in a mouse model of ICC [121]. This evidence concerns the gene METTL1 and intrahepatic cholangiocarcinoma.